Risk reduction endpoints should be part of the design of adjuvant therapy clinical trials for patients with melanoma : A commentary

✍ Scribed by Larry Nathanson

• Publisher: John Wiley and Sons
• Year: 2001
• Tongue: English
• Weight: 108 KB
• Volume: 91
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(20010301)91:5<881::aid-cncr1077>3.0.co;2-w